Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development
- 3 February 2007
- journal article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 23 (2) , 159-161
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 ExpressionArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Heme Oxygenase-1Circulation, 2006
- Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH 2 Kinase ActivationCirculation Research, 2006
- Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteriesEuropean Journal of Pharmacology, 2005
- Simvastatin Given for 3 Days Can Inhibit Thrombin Generation and Activation of Factor V and Enhance Factor Va Inactivation in Hypercholesterolemic PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitorsKidney International, 2005
- Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac MyoblastsJournal of Biological Chemistry, 2005
- Statins and Blood CoagulationArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Effects of Statins on Endothelium and Endothelial Progenitor Cell RecruitmentSeminars in Vascular Medicine, 2004
- Aspirin Protects Caco-2 Cells from Apoptosis after Serum Deprivation through the Activation of a Phosphatidylinositol 3-Kinase/AKT/p21/1PathwayMolecular Pharmacology, 2003